title: Efferent projections of ProTRH neurons in the ventrolateral periaqueductal gray.
abstract: Our previous study has shown that prothyrotropin-releasing hormone (proTRH) gene expression is increased in the ventrolateral periaqueductal gray (PAG) neurons following precipitated morphine withdrawal and continues to be activated even 24 h after withdrawal. We have hypothesized that peptide products of proTRH may participate in the recovery from morphine withdrawal. To identify neuroanatomical substrates of the proposed action of proTRH-derived peptides originating from the ventrolateral PAG proTRH neurons, projections of these neurons were investigated by a series of anterograde and retrograde tract-tracing experiments. First, Phaseolus vulgaris-leucoagglutinin (PHA-L) was injected in the ventrolateral PAG in Sprague-Dawley rats. Following transport of the tracer, simultaneous immunolabeling for PHA-L and proTRH peptides was performed and mapped in discrete brain regions. PHA-L-immunoreactive (IR) fibers showing preterminal and terminal-like arborization that contained proTRH were identified in the dorsolateral and lateral PAG, deep layer of superior colliculus (CS), parafascicular nucleus (PF), ventromedial zona incerta (ZI) and at the border of the locus coeruleus (LC) and Barrington's nucleus. Scattered double-labeled fibers were present in the lateral septal nucleus, ventromedial preoptic nucleus, lateral hypothalamus, perifornical area and in the periventricular region at the diencephalon/midbrain junction. The retrogradely transported marker, cholera toxin beta-subunit (CTb) was then injected in the dorsolateral PAG, CS, PF, ZI and medial to the LC. Double-labeled perikarya for both CTb and proTRH in the ventrolateral PAG were found for each region injected with CTb, corroborating the findings by the anterograde tracing experiment. These studies demonstrate that proTRH neurons in the ventrolateral PAG project to several regions of the brain that are involved in autonomic and behavioral regulation and thereby, may function as an integrating center to coordinate responses to opiate withdrawal.
authors.affiliation: Department of Medicine, Division of Endocrinology, Diabetes, Metabolism and Molecular Medicine, Box #268, New England Medical Center, 750 Washington St., Boston, MA 02111, USA.
authors.forename: E
authors.initials: E
authors.lastname: Mihaly
authors.forename: G
authors.initials: G
authors.lastname: Legradi
authors.forename: C
authors.initials: C
authors.lastname: Fekete
authors.forename: R M
authors.initials: RM
authors.lastname: Lechan
mesh_terms: D000818:Animals; D001341:Autonomic Nervous System / Q000166:cytology / Q000378:metabolism; D001370:Axonal Transport / Q000502:physiology; D001921:Brain / Q000166:cytology / Q000378:metabolism; D004525:Efferent Pathways / Q000166:cytology* / Q000378:metabolism; D005455:Fluorescent Antibody Technique; D008297:Male; D008845:Microinjections; D009474:Neurons / Q000166:cytology* / Q000378:metabolism; D009293:Opioid-Related Disorders / Q000378:metabolism* / Q000473:pathology / Q000503:physiopathology; D010487:Periaqueductal Gray / Q000166:cytology* / Q000378:metabolism; D010835:Phytohemagglutinins; D017729:Presynaptic Terminals / Q000378:metabolism / Q000648:ultrastructure; D011498:Protein Precursors / Q000378:metabolism*; D011761:Pyrrolidonecarboxylic Acid / Q000031:analogs & derivatives; D051381:Rats; D017207:Rats, Sprague-Dawley; D013375:Substance Withdrawal Syndrome / Q000378:metabolism* / Q000473:pathology / Q000503:physiopathology; D013973:Thyrotropin-Releasing Hormone / Q000378:metabolism*
chemical_list: D010835:Phytohemagglutinins; D011498:Protein Precursors; C100156:leukoagglutinins, plants; D013973:Thyrotropin-Releasing Hormone; C046418:pro-thyrotropin releasing hormone; D011761:Pyrrolidonecarboxylic Acid